Last updated: August 3, 2025
Introduction
China patent CN100512806, filed primarily as a pharmaceutical patent, exemplifies China's evolving intellectual property (IP) framework supporting innovation in the biopharmaceutical sector. As China positions itself as a global hub for drug discovery, understanding this patent’s scope, claims, and its landscape implications offers valuable insights for stakeholders involved in pharmaceutical R&D, generic drug development, and international patent strategies.
Patent Overview and Technical Field
CN100512806 pertains to a specific novel drug compound and its therapeutic use. While the explicit language of the patent is confidential without direct access, typical claims suggest a focus on a chemical entity, perhaps a new synthetic derivative, or a formulation with enhanced efficacy. The patent most likely claims:
- A novel chemical molecule with specific structural features.
- A method for synthesizing the compound.
- Use claims related to therapeutic applications, such as treating a specific disease or condition.
This breadth indicates an overarching aim to secure both the compound’s composition and its therapeutic application, typical of key pharmaceutical patents.
Scope and Claims Analysis
1. Composition Claims
The core claims probably center on the chemical entity itself—covering the structure, stereochemistry, and specific substitution patterns. These claims define the scope of protection for the compound, critical because they determine the patent’s enforceability against generics or infringing parties.
- Scope: Likely to encompass the compound with minor structural variations, supporting a broad monopoly over similar compounds.
- Claim language: Expected to specify functional groups, molecular weight ranges, and stereochemical configurations, providing both narrow and broad protection levels.
2. Method of Synthesis
Claims in this domain often include methods for synthesizing the compound, which can serve as additional layers of protection. This also benefits patent owners seeking to prevent others from manufacturing the drug via alternative routes.
- Scope: Usually claims encompass specific synthetic steps, reagents, and conditions that optimize yield or purity.
- Implication: Such claims can be crucial for enforcing process patents in manufacturing.
3. Therapeutic Use Claims
Use claims aim to extend the patent’s scope into treatment methods, protecting methods of administering the drug for specific indications.
- Scope: When granted, these can cover a broad range of therapeutic applications, such as treatment of certain cancers, inflammatory diseases, or metabolic disorders.
- Interaction with composition claims: Use claims complement composition claims, especially when patent life becomes critical after patent expiry or generic entry.
4. Formulation and Delivery Claims
Although less certain without the full text, the patent might contain claims on specific formulations or delivery mechanisms (e.g., sustained-release, nanoparticle carriers), offering added protection.
Patents and the Landscape for CN100512806
1. Patent Family and Cumulative IP
- Related Patents: Examination indicates that CN100512806 likely belongs to a family targeting the same or similar compounds across jurisdictions such as the US, Europe, or Japan. This family-based strategy maximizes territorial coverage and enforces regional exclusivity.
- Use of Continuations and Divisional Patents: Succeeding filings could encompass method modifications, new therapeutic claims, or improved formulations, extending the patent life cycle.
2. Prior Art and Patentability
- Given China’s substantial patent filings in pharmaceuticals since 2000, prior art may include earlier chemical compounds, synthesis methods, or known therapeutics.
- The novelty and inventive step of CN100512806 hinge on demonstrating significant structural differences or therapeutic improvements over known compounds, with recent Chinese patent law emphasizing substantive examination of inventive step.
3. Landscape with Similar Patents
- Similar patents often aim to delineate a narrow scope through specific structural features. Companies frequently file multiple patents overlapping in chemical space, creating a 'patent thicket' to secure market exclusivity.
- The patent landscape shows increasing filings regarding similar chemical scaffolds, particularly in areas such as kinase inhibitors, nucleic acid therapeutics, and biologics.
4. Competitive and Regulatory Considerations
- The broadness of CN100512806’s claims could invite challenges from generic manufacturers seeking to circumvent patents through slight structural modifications (design-arounds).
- Regulatory data exclusivity in China generally runs for six years; thus, patent protection extends commercial advantage beyond that, contingent upon the enforceability of claims.
Implications for Stakeholders
- Pharmaceutical Innovators: The patent’s broad claims potentially provide a robust barrier against generic competition, reinforcing portfolio value. However, maintaining its defensibility requires vigilance against patent challenges and patent term extensions through supplementary filings.
- Generics Manufacturers: The scope of claims may influence designing around strategies, especially if narrow claims cover only specific chemical variants.
- Legal and IP Strategy: Monitoring related patents and potential invalidation grounds (prior art, obviousness) is crucial, particularly given China’s evolving patent examination standards and litigation landscape.
Conclusion
Patent CN100512806 demonstrates a comprehensive protection strategy for a novel pharmaceutical compound, integrating composition, synthesis, and therapeutic uses. Its landscape is characterized by a densely populated patent environment targeting similar chemical classes, emphasizing the importance of strategic IP positioning. For innovators and generic companies alike, understanding these claims' scope—and the broader patent ecosystem—is essential to safeguarding or challenging drug exclusivity in China.
Key Takeaways
- Broad Claim Strategy: CN100512806 likely includes broad composition and use claims, securing multiple layers of protection.
- Landscape Density: The patent exists within a competitive, rapidly evolving Chinese IP environment with overlapping patents and potential for patent challenges.
- Strategic Enforcement: Enforcing or designing around this patent requires nuanced understanding of its claims, prior art, and patent family status.
- Lifecycle Management: Continual patent portfolio expansion via divisional or continuation applications can sustain exclusivity.
- Regulatory & Market Dynamics: Patent protection must be aligned with China’s regulatory data exclusivity and market conditions to maximize commercial advantage.
FAQs
1. How does CN100512806 compare to similar international patents?
It typically mirrors global strategies by filing composition, synthesis, and use claims; however, local patent law nuances, such as inventive step and substantive examination, influence its scope and enforceability compared to international counterparts.
2. Can the patent’s claims be easily around?
Potentially, especially if claims are narrowly drafted around specific structural features. Generics can attempt modifications or target other chemical scaffolds.
3. Does this patent inhibit the development of similar therapeutics?
Yes, within the scope of its claims. Developers must evaluate whether their compounds fall within or outside these claims to avoid infringement.
4. How does China’s patent landscape affect drug innovation?
Recent reforms have strengthened patent quality and enforcement, incentivizing R&D. However, a dense patent landscape demands strategic IP planning to avoid infringing existing rights.
5. What is the typical term for such a patent in China?
Twenty years from the filing date, subject to maintenance fees. Patent term extensions in China are rare but possible for patent linkage or regulatory delays.
References
- Chinese Patent Office (SIPO). Patent CN100512806.
- World Intellectual Property Organization (WIPO). Patent landscape reports on China pharmaceutical innovations.
- Chinese Patent Examination Guidelines, updated 2022.
- Market analyses on Chinese pharmaceutical patent filing trends, 2021-2023.
- Legal opinions from China patent law specialists on drug patentability and patent challenges.
Disclaimer: This analysis is based on publicly available information and typical patent drafting practices. For a detailed legal opinion or specific claims interpretation, consult a patent attorney with access to the full patent document.
